Avior Wealth Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Avior Wealth Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-50	Closed	-$347	–	790
2018 Q3	$1K	Sell	50 -650	-93%	-$5.18K	﹤0.01%	723
2018 Q2	$5K	Buy	+700	New	+$4.88K	﹤0.01%	659
2017 Q3	–	Sell	-400	Closed	-$5K	–	525
2017 Q2	$5K	Buy	400 +100	+33%	+$1.18K	﹤0.01%	370
2017 Q1	$3K	Buy	+300	New	+$3.2K	﹤0.01%	443

Other funds holding INSY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Avior Wealth Management's INSY Position: Q4 2018 in Review

Avior Wealth Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 50 shares — an estimated $347 sold.

Avior Wealth Management first reported a position in INSY in Q1 2017 and held it in 4 quarters. The position peaked at $5K in Q2 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

Avior Wealth Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Avior Wealth Management sold 50 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $347.
Avior Wealth Management first reported a position in Insys Therapeutics, Inc. in Q1 2017 and held it in 4 quarters.
Avior Wealth Management's Insys Therapeutics, Inc. position peaked at $5K in Q2 2018.
113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on Avior Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.